study question: Do differences in endometrial gene expression exist after ovarian stimulation with four different regimens of triggering final oocyte maturation and luteal phase support in the same patient?
Introduction
In assisted reproductive technology (ART), a bolus of hCG, 5000 -10 000 IU, is administered either subcutaneously or intramuscularly to mimic the mid-cycle surge of LH. Due to their structural similarities, hCG and LH bind to and activate the same receptor, the LH/hCG receptor (Kessler et al., 1979) , and it is assumed that exogenous hCG promotes the same biological processes as the natural mid-cycle surge of LH. There are, however, significant molecular and structural differences between LH and hCG. Importantly, the half-life of hCG is longer (days) than that of LH (hours), due to an increased content of oligosaccharides (Damewood et al., 1989) . Moreover, in contrast to a bolus of hCG, in the natural cycle, both LH and FSH are secreted during the mid-cycle surge of gonadotrophins. The FSH surge is known to promote nuclear maturation, i.e. the resumption of meiosis, as well as LH receptor formation in the luteinizing granulosa cells, securing the function of the corpus luteum during the subsequent luteal phase (Strickland and Beers, 1976; Eppig, 1979; ZelinskiWooten et al., 1995; Yding et al., 1999; Yding, 2002) .
A bolus of GnRH agonist was previously shown to effectively stimulate ovulation and final oocyte maturation, inducing an initial secretion of LH and FSH (flare-up) from the pituitary, similar to that seen during the natural mid-cycle surge of gonadotrophins, prior to downregulation of the GnRH receptor (Gonen et al., 1990; Itskovitz et al., 1991) . However, with the introduction of GnRH agonist for pituitary down-regulation prior to IVF/ICSI treatment (Porter et al., 1984) , this concept was not applicable any longer, as the simultaneous use of GnRH agonist for down-regulation and triggering of final oocyte maturation is not possible.
Recently, when the GnRH antagonist was introduced, it became feasible again to trigger ovulation with a bolus of a GnRH agonist, as a bolus of GnRH agonist will displace the GnRH antagonist from the GnRH receptor, eliciting a surge of LH and FSH (Humaidan et al., 2005 (Humaidan et al., , 2010 Humaidan, 2009; Engmann et al., 2008) .
The first RCT to re-introduce GnRH agonist triggering in patients co-treated with a GnRH antagonist had to be discontinued due to an extremely high early pregnancy loss rate (79%), despite supplementation with a standard luteal phase support including vaginal progesterone as well as estradiol (Humaidan et al., 2005) . Following this trial, a number of studies were performed, showing an optimal intra-follicular environment after GnRH agonist trigger (Andersen et al., 2006) , a live birth rate after frozen embryo replacement comparable with that seen after the hCG trigger (Griesinger et al., 2007) and intra-follicular amphiregulin levels after the GnRH agonist trigger closer to those seen after the natural mid-cycle surge of gonadotrophins than those seen after the hCG trigger (Humaidan et al., 2011) . Furthermore, several studies reported the retrieval of more MII oocytes after the GnRH agonist trigger when compared with the hCG trigger (Imoedemhe et al., 1991; Humaidan et al., 2005 Humaidan et al., , 2010 Humaidan et al., , 2011 Oktay et al., 2010) . However, on the basis of the abovementioned studies, it was hypothesized that the GnRH agonist trigger induces a further disruption of the luteal phase seen after controlled ovarian stimulation, due to a significant reduction in circulating endogenous LH during the early-mid luteal phase when compared with the natural cycle (Humaidan, 2009 ). In contrast, after the hCG trigger, this LH deficiency is covered by the prolonged LH-like activity of hCG (Weissman et al., 1996; Fauser et al., 2002) .
To confirm the LH deficiency theory after the GnRH agonist trigger, a number of trials were conducted during which the luteal phase support was modified, as patients, in addition to a standard luteal phase support, were supplemented with a small bolus of LH-like activity in the form of 1500 IU hCG on the day of oocyte retrieval (Humaidan et al., , 2010 Humaidan, 2009 ). The results of these studies seemed to confirm the LH deficiency theory, as the luteal phase after GnRH agonist triggering was normalized in these patients not only in terms of serum progesterone levels, but also in terms of the reproductive outcome, as clinical pregnancy rates were similar to those seen after the hCG trigger (Humaidan et al., , 2010 Humaidan, 2009) .
The objective of the present study was to mimic, in an oocyte donor model, the set-up of the clinical trials previously performed with the GnRH agonist trigger to analyze the impact on endometrial gene expression. To avoid any inter-individual variation in gene expression, each donor performed four consecutive oocyte donation cycles within 1 year.
Materials and Methods

Patient population
Four oocyte donors were included in the trial performed during the period 2010 -2011. Each donor performed four oocyte donation cycles, randomized to different models of final oocyte maturation and luteal phase support; thus, a total of 16 oocyte donation cycles performed in four oocyte donors were analyzed.
The inclusion criteria were: the presence of a minimum of five antral follicles in each ovary, normal chromosomal analysis, normal serological findings within 3 months prior to stimulation, normal vaginal ultrasound (US) and no presence of any intrauterine contraceptive device.
The exclusion criteria were: the presence of polycystic ovarian syndrome diagnosed according to the revised Rotterdam criteria (Rotterdam ESHRE/ASRM -Sponsored PCOS Consensus Workshop Group 2004), presence of endometriosis AFS classification stage .2, age ≥36 years, US verified hydrosalpinges, presence of any intrauterine contraceptive device and/or OCP usage for the past 6 months prior to the initiation of stimulation.
The research project was approved by the local Institutional Review Board and registered in the European Community Clinical Trial System (EudraCT) number 2009-009429-26, protocol number 997 (P06034).
Ovarian stimulation
After a vaginal US examination and the confirmation of baseline FSH, LH and estradiol, stimulation commenced in the afternoon of Day 2 of the cycle with 200 IU rec-FSH (Puregon w , MSD, Oss, the Netherlands). The FSH dose remained fixed until Day 5 of the cycle. Thereafter, the FSH dose was adjusted according to the ovarian response. To inhibit a premature LH surge, daily GnRH antagonist co-treatment (Orgalutran w 0.25 mg, MSD) was implemented from the morning of Day 5 of stimulation. Final oocyte maturation was induced as soon as ≥3 follicles of ≥17 mm were present. Randomization to one of the four protocols, through a computer generated list, took place on the day of triggering of final oocyte maturation. Once patients had been allocated to one of the possible protocols, this protocol was automatically deleted from the computer generated list. Oocyte retrieval was carried out 34 h later. In addition, the gynecologist in charge of the oocyte retrieval and the scientist responsible for the gene expression analyses of endometrial biopsies were blinded to the treatment allocation.
Final oocyte maturation
The same donor underwent four stimulation protocols with different modes of final oocyte maturation and luteal phase support: (A) 10 000 IU hCG and standard luteal phase support, (B) triptorelin 0.2 mg, followed by 1500 IU hCG 35 h after triggering of final oocyte maturation and standard luteal phase support, (C) triptorelin 0.2 mg with standard luteal phase support and (D) triptorelin 0.2 mg without luteal phase support.
Luteal phase support
The standard luteal phase support consisted of vaginal administration of 600 mg natural micronized progesterone in three separate doses (Utrogestan w , Besins-Iscovesco, Paris, France, 100 mg 3 × 2/day) with the addition of estradiol-valerate (Progynova w , Schering N.V, Diegem, Belgium) 4 mg daily per o.s., starting 1 day after oocyte retrieval and continuing until the day of endometrial sampling, day ovum pick up + 5.
US assessment
US was performed on Day 6 of stimulation and thereafter as necessary in order to ensure that final oocyte maturation was triggered on the day when the patient had ≥3 follicles of ≥17 mm.
Endometrial sampling and RNA isolation
Endometrial biopsies were taken with a pipelle cannula (Pipelle de Cornier w , Prodimed, Neuilly-en-Thelle, France) under sterile conditions on the 5th day after the oocyte retrieval. Biopsies were snap-frozen in liquid nitrogen under sterile conditions for RNA isolation. To avoid a short-time bias in endometrial gene expression due to the biopsy, donors underwent stimulation and biopsy with an interval of 3 months.
RNA extraction was performed using the RNeasy Mini kit (Qiagen, Valencia, CA, USA). Total RNA concentration was measured with the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) and integrity of the RNA samples was controlled using the Agilent 2100 Bioanalyzer with the RNA 6000 Nano Kit (Agilent Technologies Inc., Palo Alto, CA, USA).
Microarrays and data analysis
In total, 16 samples were analyzed for their gene expression with microarrays. Therefore, 500 ng of the total RNA was reverse-transcribed with the IVT express kit (Affymetrix, Santa Clara, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promotor site. Then, cDNA was in vitro transcribed and labeled with biotin followed by the fragmentation of the biotinylated cRNA. Next, the quality of this cRNA was assessed with the Agilent 2100 Bioanalyzer and NanoDrop. Quality control of prepared cRNA samples was based on (i) a yield of .15 mg and (ii) a Bioanalyzer microchannel electrophoresis elution profile that was typical for the chosen tissue and reproducible for the replicate samples (Van Lommel et al., 2006) . The fragmented cRNA was hybridized overnight to the Affymetrix Human Genome (HG) U133 Plus 2.0 Array (Affymetrix). This array contains more than 54 000 probe sets for the whole HG. Subsequently, the arrays were washed and stained according to the protocol (Affymetrix Expression Analyses Technical Manual 702646Rev1) and scanned on an Affymetrix 3000 GeneScanner.
Data analysis was performed with GeneSpring GX 11.5 (RMA algorithm; Van Vaerenbergh et al., 2009 
Validation of microarrays: quantitative PCR
To verify the results obtained from the microarrays on the RNA level, three selected genes were validated with a more quantitative real-time PCR technique. Genes were selected based on evidence from the literature related to the endometrial expression of genes during the periimplantation period and the uterine receptivity (Lindhard et al., 2002; Pilka et al., 2003; Ledee-Bataille et al., 2004 and based on their high fold change and/or their appearance in the involved pathways.
A two-step real-time PCR was performed. First, a reverse-transcription reaction from total RNA was achieved with the High-Capacity cDNA Archive kit (Applied Biosystems, Foster City, CA, USA) following the manufacturer's protocol. The quantitative real-time PCR was performed with the TaqMan Gene Expression Assays (Applied Biosystems). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was chosen as the control housekeeping gene using the TaqMan Endogenous Control Assay (Applied Biosystems). Both assays are cDNA specific, since the probes span an exon junction. All real-time PCR assays were run using the TaqMan Gene Expression Master Mix (Applied Biosystems) on the 7900 HT Fast System (Applied Biosystems). Thermal cycling parameters were set as follows: 2 min at 508C, 10 min at 958C, followed by 40 cycles of denaturation, annealing and extension (15 s at 958C and 1 min at 608C, respectively). All samples were analyzed in triplicate. The relative quantification was performed by the standard curve method. For each sample, the amount of target gene and endogenous control (GAPDH) was determined from their respective standard curves. First, the target gene amount was divided by the endogenous control amount to obtain a normalized value. In a second step, the samples were normalized again to the sample with the lowest normalized expression, the calibrator sample or 1× sample. Therefore, each of the normalized values was divided by the calibrator-normalized value to generate the relative expression levels.
Data analysis and statistical methods
The microarray data analysis was performed with GeneSpring GX 11.5 (RMA algorithm). Pathway and network analysis was performed with the gene ontology software Ingenuity Pathways Analysis (Ingenuity w Systems, www.ingenuity.com). Samples were grouped and background intensity Ovulation trigger and endometrial gene expression values were removed (cutoff lowest 20 percentile). A one-way ANOVA test (P , 0.05) was performed with the Benjamini -Hochberg multiple testing correction for the false discovery rate at 0.05.
Results
Differentially expressed genes
The four study groups were compared with each other, with Group A as the control group.
From quality-control steps (with PCA and hierarchical clustering), it was shown that one sample was considered as an outlier. Indeed, when correlating this with the available histological dating results, we found that the dating for this biopsy sample was not possible due to the fact that this sample contained isthmus material. This sample, therefore, was excluded from the following analysis.
Thus, a total of 15 samples were used for analysis. Samples were grouped and background intensity values were removed (cutoff lowest 20 percentile). A one-way ANOVA test (P , 0.05) was performed with the Benjamini -Hochberg multiple testing correction. There were 2631 entities or probe sets which had a fold change cutoff of 2.0 in at least one condition pair, when comparing Group A with Group B, or A with C, A with D, B with C, B with D and C with D (Supplementary data, Table SI) .
From this gene list, the groups were compared separately (Supplementary data, Tables SII -SVII). The number of significantly differentially expressed probe sets (P , 0.05; FC ≥ 2.0) is shown in Table I . This difference in gene expression can be visualized by a profile plot (Fig. 1) . A profile plot is a graphical data analysis technique to examine the relative behavior of all variables in a multivariate data set. This data analysis in Fig. 1 shows all the significantly differentially expressed probe sets or genes, represented by lines. Each line represents a gene and each line is colored by its expression in Group A. The expression of each gene can therefore be followed in the four treatment groups. This analysis shows a large difference between Group D and the other groups and a small difference in gene expression between Groups A and B. Groups A and B are similar in gene expression, while Groups C and D show more differences in gene expression, when compared with each other and also compared with Groups A and B. In Group D, some genes show a very extreme up-or downregulation. These genes are INHBA (inhibin-ba), MMP1 and MMP3 (matrix metalloproteinases 1 and 3), LEFTY2 [endometrial bleeding associated factor (left-right determination, factor A) transforming growth factor beta (TGF-b) superfamily], which were up-regulated in Group D, and CXCL13 [chemokine (C-X-C motif) ligand 13], MMP26 and SCGB1D2 (secretoglobin family 1D member 2 or lipophilin B), which were down-regulated in Group D.
When comparing Groups B and C, a total of 785 probe sets were significantly differently expressed (Table I and Supplementary data,  Table SV) . From these genes, the top genes that were found to be highly up-or down-regulated in Group B included growth factors like TGFb2, metalloproteinases like MMP26 and CYP3A5 (cytochrome P450), known for its role in steroidogenesis. Moreover, XDH (xanthine dehydrogenase) was highly up-regulated in Group B. This gene was previously found in a molecular network together with COX-2 in endometrial biopsies taken on the day of oocyte retrieval in stimulated IVF cycles (Van Vaerenbergh et al., 2011) .
Pathways, networks and functions
From the gene list of 2631 probe sets, the involved pathways and networks (Tables II and III) were investigated. From this data set, 25 networks could be formed. The most significant functions and diseases associated with these data are cancer, cellular movement, reproductive system disease, cell-to-cell signaling, cellular development, growth and proliferation. Furthermore, the analysis demonstrated a large number of pathways involved in, for example, natural killer cell signaling, arachidonic acid metabolism, phospholipase C signaling, TGF-b signaling, integrin signaling (Fig. 2) , metabolism of xenobiotics by cytochrome P450, p53 signaling and Wnt/b-catenin signaling.
Quantitative PCR
Three genes were selected for further validation with quantitative real-time PCR, as described in the 'Materials and methods' section: MMP26 (matrix metallopeptidase 26), ITGB6 (integrin, b6) and IL12RB1 (interleukin 12 receptor, b1). The data showed a highly significant difference between Groups A and D in the expression of ITGB6 (unpaired t-test; P ¼ 0.0018). The difference for IL12RB1 and MMP26 expression was not significant (P . 0.05), although a trend was noticeable.
Discussion
This study performed in an oocyte donor model revealed significant differences in early luteal phase endometrial gene expression according to the mode of triggering final oocyte maturation and the use or not of the luteal phase support. Four donors each underwent four consecutive oocyte donation cycles, using different protocols (A -D) to mimic the conditions previously described in randomized controlled trials (Beckers et al., 2003; Humaidan et al., 2005 Humaidan et al., , 2010 Kolibianakis et al., 2005) . Whereas Groups A and B were similar in gene expression, differences were seen not only between Group A or B and Group C or D, but also between Groups C and D. Importantly, the genes involved are well-known for their role in implantation.
The luteal phase of all stimulated IVF cycles is abnormal (Edwards et al., 1984) regardless of the type of GnRH analog used for co-treatment when compared with only 8% of natural cycles (Rosenberg et al., 1980) . The most plausible reason for the disrupted luteal phase seen after ovarian stimulation seems to be the supraphysiological luteal steroid level, mainly progesterone, induced by the ovarian stimulation with exogenous gonadotrophins, exerting a negative feedback on the hypothalamic-pituitary axis level, leading to a reduction in LH secretion by the pituitary (Tavaniotou et al., 2001; Tavaniotou and Devroey, 2006; Fatemi et al., 2008) . Importantly, GnRH agonist triggering per se induces a significant reduction in circulating endogenous LH in the early-to-mid-luteal phase due to differences in the profile and duration of the LH surge when compared with the natural mid-cycle surge of gonadotrophins (Hoff et al., 1983; Gonen et al., 1990; Itskovitz et al., 1991) and it has previously been demonstrated that withdrawal of or a reduction in circulating LH during the luteal phase leads to luteolysis and implantation failure (Duffy et al., 1999) . In contrast, when a large bolus of hCG (5000 -10 000 IU) is used for the induction of ovulation, this ovulatory bolus of LH activity will support the corpora lutea for 7 -10 days due to the long half-life of hCG (Eppig, 1979; Mannaerts et al., 1998) . From then on, the corpora lutea will be dependent on the endogenous LH secretion by the pituitary or by the gradually increasing hCG production from an implanting embryo, which actively secretes hCG, detectable in the maternal serum as early as from the 8th day after ovulation 
Continued
Ovulation trigger and endometrial gene expression (Bonduelle et al., 1988) . However, due to the absence of direct vascular communication, the secretion of hCG into the maternal circulation is initially limited (Nepomnaschy et al., 2008) , indicating that in hCG-triggered ovarian stimulation cycles, the actions of LH during the early luteal phase is covered by the triggering bolus of hCG and after this period, by the hCG gradually produced by the implanting embryo. However, after GnRH agonist triggering, the combined effect of ovarian stimulation and GnRH agonist triggering reduces the endogenous LH level dramatically (Humaidan, 2009 ) and, although a standard luteal phase support is used, the reduction in LH will have a detrimental effect on the reproductive outcome (Humaidan et al., 2005; Kolibianakis et al., 2005) . In the present study, the control group (A) represented the standard GnRH antagonist protocol in which final oocyte maturation was performed with a bolus of 10 000 IU hCG, followed by a standard luteal phase support. Group B represented a standard GnRH C21orf33, CRMP, CRMP1, DPYSL3, DPYSL4, DYRK2, FILIP1L,  FNDC3B, HOXB5, KDM6B, KIF3C, LANCL1, LOXL2, LPCAT3, LRBA, LRRC1,  MFAP2, MRPS6, PI4K2B, PKIG, PLXNC1, RAB25, RAMP2, RBMS1, SLC39A8,  SLC39A14, SMOC2, ST3GAL5, TAX1BP3, TGFB1, UCK2, ZFP36L2 Cell morphology, skeletal and muscular system development and function, molecular transport Cellular development, gene expression, cell-to-cell signaling and interaction 25 ABCC3, ANXA9, Bcl9-Cbp/p300-Ctnnb1-Lef/Tcf, CEP70, CERK, Coup-Tf, CPB2, CYP19, CYP26A1, DUSP5, Esr1-Esr1-estrogen-estrogen, GM2A, HPRT1, IER2, Igh, IL1B, JINK1/2, KLF10, LGALS9, MMD, N-cor, NLRP1, NOD2, NRIP1, PANX1, PCDH7, Rar, RCAN2, Retinoic acid-RAR-RXR, Rxr, SLC20A1, SLC2A9, T3-TR-RXR, Thyroid hormone receptor, UAP1
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antagonist protocol with the GnRH agonist trigger, followed by a modified luteal phase support, consisting of a bolus of 1500 IU hCG administered on the day of oocyte retrieval along with the standard luteal phase support. This concept has recently been shown to secure the ongoing clinical pregnancy rate after the GnRH agonist trigger (Humaidan et al., , 2010 . Group C represented the GnRH agonist trigger, followed by a standard luteal phase support only. This concept previously resulted in an extremely low clinical ongoing pregnancy rate and a high early pregnancy loss rate (Humaidan et al., 2005; Kolibianakis et al., 2005) . Finally, Group D received the GnRH agonist trigger and no luteal phase support, mimicking the conditions of the study by Beckers et al. (2003) , also reporting low clinical ongoing pregnancy rates. When comparing the microarray analysis between groups, significant differences were seen in gene expression between Group A or B and Group C or D, whereas only a slight difference was seen Ovulation trigger and endometrial gene expression between Groups A and B, supporting the clinical finding of a normalization of the luteal phase after the GnRH agonist trigger if the patient is supplemented with a bolus of 1500 IU hCG (Humaidan et al., , 2010 . In the validation of several genes with a more quantitative technique such as RT -PCR, we found a large standard deviation between the samples of the same groups. Therefore, some individual genes did not reach significance in the real-time RT -PCR. This large variation is possibly due to an inter-individual variation between patients.
Most of the genes with extreme up-or down-regulation in Group D (Fig. 1) and the genes found to be significantly differentially regulated between Groups B and C are well-known for their roles during implantation (Tabibzadeh, 2002; Macklon et al., 2008; Van Vaerenbergh et al., 2011) . Other genes found to be highly up-regulated in the microarray data are MMPs, integrins and interleukins. MMPs are involved in a number of pathways, like the leukocyte extravasation signaling pathway. Moreover, it is known from the literature (Pilka et al., 2003) that MMPs play a role in extracellular matrix degradation and MMP26 is expressed in a cyclic pattern in the human endometrium. Its expression is increased from the proliferative to the early secretory phase. Therefore, MMP26 may play a role in implantation either directly or as an activator of cytokines, growth factors and other vasoactive factors. ITGB6 is one of the integrins expressed in the integrin signaling pathway (Fig. 2) . Integrins are well known cell adhesion molecules present in the endometrium throughout the menstrual cycle, established as potential markers of endometrial receptivity and known participants in embryo-endometrial interactions (Lindhard et al., 2002) . Interleukins are known fertility-related factors as well (Ledee-Bataille et al., 2004 ). These findings demonstrate that known fertility-related genes are differently regulated during the window of implantation when the mode of triggering is modified and when there is no luteal phase support.
Taken together, a bolus of GnRH agonist (triptorelin, 0.2 mg) is sufficient to secure final oocyte maturation, but this triggering concept further disrupts the luteal phase insufficiency commonly seen in all ovarian stimulation cycles, with or without a standard luteal phase support (Groups C and D). However, the combination of the GnRH agonist trigger and a modified luteal phase support (Group B) shifts the endometrial gene expression pattern toward the pattern seen after the hCG trigger (Group A).
In conclusion, the gene expression of endometrial biopsies taken on Day 5 after oocyte retrieval from oocyte donors, using different protocols for final oocyte maturation and luteal phase support, showed significant differences between groups. Many genes involved are known to play a role in implantation and the receptivity of the endometrium. Whether the differences in gene expression are directly associated with an increase in LH activity levels, an increase in progesterone levels or both, needs to be further elucidated. The lessons learned from the GnRH agonist trigger may pave the way for a wider understanding of the luteal physiology of the stimulated cycle. This could potentially lead to future changes in the luteal phase support which might increase the numbers of embryos implanting after IVF.
Supplementary data
Supplementary data are available at http://humrep.oxfordjournals. org/.
